These studies establish ANGPTL3 inhibitors as robust candidates for treating resistant hypercholesterolemia, especially in patients who do not adequately respond to statins, PCSK9 inhibitors, or other therapies. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.